Valeant’s Cost-Cutting Ethos May Yet Give Wall Street Indigestion by JESSE EISINGER

By JESSE EISINGER

Valeant Pharmaceuticals’ lean business model risks harming its relationship with the Food and Drug Administration and hampering its competitiveness, Jesse Eisinger writes in The Trade.

Published: July 30, 2014 at 4:00AM

from NYT Business Day http://ift.tt/1nIWO9c

from WordPress http://ift.tt/1ttBdoi

via Hadi Aboukhater